Venous Thromboembolism Prophylaxis & Management

Venous Thromboembolism Prophylaxis & Management

Venous thromboembolism ($VTE$), encompassing deep vein thrombosis ($DVT$) and pulmonary embolism ($PE$), represents one of the most common and preventable causes of secondary morbidity and mortality in neurocritical care. Without thromboprophylaxis, the incidence of hospital-acquired $DVT$ in acute stroke, traumatic brain injury ($TBI$), and spinal cord injury cohorts exceeds $50\%\text{ to }75\%$. Pulmonary embolism accounts for up to $10\%\text{ to }15\%$ of all in-hospital deaths following intracerebral hemorrhage. Managing $VTE$ in neuro-ICU patients requires walking a precarious tightrope between preventing fatal pulmonary emboli and avoiding catastrophic secondary intracranial re-bleeding.

VTE Epidemiology & Pathophysiology in Neurocritical Care

Neurocritical care patients fulfill all three arms of Virchow's Triad with unparalleled severity:

Virchow's Triad in Acute Neurological Injury
├── Venous Stasis: Flaccid hemiplegia, loss of calf muscle pump, coma, prolonged bed rest
├── Hypercoagulability: Systemic inflammatory cascade, release of brain tissue factor, elevated Factor VIII & fibrinogen
└── Endothelial Injury: Femoral central venous lines, polytrauma, immobilization-induced shear changes

1. Venous Stasis: Dense motor hemiplegia, paraplegia, therapeutic neuromuscular blockade, high-dose analgosedation, and coma eliminate voluntary muscle contraction. Loss of the peripheral calf-muscle pump promotes marked venous pooling and stasis in the deep sinusoids of the lower extremities.
2. Hypercoagulability: The injured brain parenchyma contains the highest concentration of tissue factor (Factor III) of any organ in the human body. Disruption of the blood-brain barrier releases tissue factor directly into the systemic circulation, triggering widespread, low-grade intravascular thrombin generation. Concurrently, acute phase reactants such as fibrinogen and Factor VIII spike, while endogenous fibrinolysis is suppressed.
3. Endothelial Injury: Prolonged femoral central venous catheterization, invasive arterial monitoring, and polytrauma inflict direct mechanical endothelial denudation, exposing pro-thrombotic subendothelial matrix.

Mechanical Thromboprophylaxis: IPC vs. Compression Stockings

Mechanical thromboprophylaxis provides hemostatically neutral protection against $DVT$ and must be instituted immediately upon presentation in every neuro-ICU patient unless absolute local contraindications (such as severe peripheral artery disease, lower extremity burns, or acute circumferential ulcers) exist.

Intermittent Pneumatic Compression (IPC) & The CLOTS 3 Trial

Intermittent pneumatic compression devices apply sequential, circumferential pneumatic pressure bladders from the ankle to the upper calf, inflating to $45\text{ to }50\text{ mmHg}$ at regular intervals:

• Physiologic Effects: IPC empties lower extremity venous reservoirs, augments peak venous blood flow velocity, eliminates stasis, and stimulates endogenous vascular endothelial release of tissue plasminogen activator ($tPA$) and endothelial nitric oxide synthase ($eNOS$), promoting local endogenous fibrinolysis.

• The CLOTS 3 Trial (Lancet 2013): A multicenter randomized trial of 2,876 immobile acute stroke patients comparing routine IPC versus no IPC. Patients allocated to IPC experienced a significant reduction in proximal deep vein thrombosis ($8.5\%$ vs. $12.1\%$, adjusted odds ratio $0.69$, $95\%$ CI $0.55\text{--}0.86$, $p = 0.009$). Crucially, IPC was associated with a statistically significant improvement in $6\text{-month}$ survival ($p = 0.042$).

• Evidence: CLOTS 1 found no benefit of thigh-length stockings versus avoidance. CLOTS 2 compared thigh-length with below-knee stockings and favored thigh-length for proximal DVT; it did not show that both were equivalent to no stockings. Guidelines favor IPC rather than stockings alone for immobile ICH patients.

Timing of Pharmacologic Thromboprophylaxis after Intracranial Hemorrhage

While mechanical prophylaxis is vital, IPC alone is insufficient to prevent all thromboembolic events. The pivotal question is when it becomes safe to initiate low-dose chemoprophylaxis without inciting hematoma expansion.

Spontaneous Intracerebral Hemorrhage (sICH)

• The Golden $24\text{-to-}48\text{-Hour}$ Rule: Most spontaneous intracerebral hematoma expansion occurs within the first $24\text{ hours}$ post-ictus. Prospective registry data and randomized feasibility trials demonstrate that low-dose chemoprophylaxis is safe when initiated at $24\text{ to }48\text{ hours}$ after symptom onset.
• Prerequisite Stability Scan: A non-contrast head CT must be obtained at $24\text{ hours}$ to verify radiographic hematoma stability. If the repeat CT shows no expansion and no new intraventricular extravasation, pharmacologic prophylaxis should be initiated.
• Recommended Agents: Subcutaneous low-molecular-weight heparin (enoxaparin $30\text{ mg}$ subcutaneously every $12\text{ hours}$ or $40\text{ mg}$ once daily) or low-dose unfractionated heparin ($5000\text{ units}$ subcutaneously every $8\text{ hours}$). Low-molecular-weight heparin is preferred over UFH because it provides superior anti-Xa bioavailability, more predictable anticoagulation, and lower rates of heparin-induced thrombocytopenia ($HIT$). In patients with severe renal insufficiency ($CrCl < 30\text{ mL/min}$), dose-adjusted UFH is preferred due to lack of renal accumulation.

Traumatic Brain Injury (TBI)

Under Brain Trauma Foundation ($BTF$) and Western Trauma Association ($WTA$) consensus protocols, low-dose $LMWH$ or $UFH$ is safe to initiate within $24\text{ to }48\text{ hours}$ of injury or admission, provided a scheduled repeat head CT at $24\text{ hours}$ confirms stability of cerebral contusions, traumatic subarachnoid hemorrhage, or subdural hematomas.

Aneurysmal Subarachnoid Hemorrhage (aSAH)

• Post-Securing Initiation: In aneurysmal $SAH$, pharmacologic thromboprophylaxis is strictly contraindicated while an aneurysm remains unsecured due to the catastrophic mortality of re-rupture ($> 70\%$). Once the aneurysm is definitively secured via endovascular coiling or surgical clipping, subcutaneous chemoprophylaxis should be initiated $24\text{ hours}$ post-procedure.
• External Ventricular Drains (EVD): The presence of an external ventricular drain is not a contraindication to prophylactic low-dose $LMWH/UFH$. Multiple prospective studies have established that low-dose chemoprophylaxis does not increase clinically meaningful catheter-tract hemorrhages during drain maintenance or routine removal.

Post-Craniotomy

Following elective or trauma-related craniotomy, subcutaneous heparin or enoxaparin is initiated at $24\text{ to }48\text{ hours}$ postoperatively, once postoperative neuroimaging confirms complete hemostasis and absence of extra-axial hematoma accumulation.

Management of Acute VTE in the Acute ICH Window

When acute proximal DVT or PE occurs after recent ICH, weigh hemorrhage stability, time since onset, clot severity, and competing risks. AHA/ASA states that delaying therapeutic UFH or LMWH for one to two weeks might be considered in selected ICH patients. This is not an absolute ban on all earlier anticoagulation or one universal timing rule. A retrievable IVC filter can bridge a proximal DVT when anticoagulation is temporarily unsuitable.

Inferior Vena Cava (IVC) Filters

In this clinical scenario, placement of a retrievable Inferior Vena Cava (IVC) filter is indicated as a temporary mechanical sieve to capture migrating macro-emboli and prevent fatal saddle pulmonary emboli:

• Filtration Mechanics: The filter is deployed infra-renally via femoral or internal jugular percutaneous access. It does not treat, dissolve, or halt local extension of the underlying lower extremity thrombus; it purely functions as a mechanical trap.
• Mandatory Filter Retrieval Protocol: Retrievable filters must be systematically tracked in an institutional registry. Once the patient has passed the high-risk intracranial hemorrhage window and therapeutic anticoagulation can be safely initiated, the filter should be retrieved to prevent long-term filter thrombosis, lower-extremity venous stasis syndrome, filter migration, or caval perforation.

Resuming Therapeutic Anticoagulation

Treating acute VTE, restarting therapy for a mechanical valve, and restarting anticoagulation for atrial fibrillation are different decisions. For nonvalvular AF after spontaneous ICH, AHA/ASA suggests that initiation around seven to eight weeks may be considered after individual benefit–risk assessment. Mechanical valves or other exceptionally high thrombotic risks may support earlier resumption. Hemorrhage location, suspected CAA, imaging, blood pressure, and procedural plans influence the balance. Left atrial appendage closure may be considered in selected AF patients unable to take anticoagulation; it is not automatically preferred for every lobar ICH.

When anticoagulation is restarted, select agent, dose, and monitoring with the responsible teams. Repeat examination and imaging as indicated. An IVC filter does not treat the original clot and should have a retrieval plan once it is no longer needed.